SPRY

ARS Pharmaceuticals
SPRY

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.79B
EV
$1.58B
Shares Outstanding
108.70M
Beta
0.99

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$32.00
P/E 2025E
-
P/Revenue 2025E
22.43x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About ARS Pharmaceuticals, Inc.

gainify
SPRY

ARS Pharmaceuticals, Inc.

SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, includin...

Sector

Healthcare

Industry

Biotechnology

CEO

Lowenthal, Richard

Employees

158

IPO Date

2020-12-04

Headquarters

11682 El Camino Real, Suite 120, San Diego, California, 92130, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.